|
3.1 Tabac
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
|
|
3.8 Prévention - Alimentation
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.5 ASCO
|
|
|
|
5.7.2 SABCS-divers
|
|
|
|
5.7.3 SABCS-AACR
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
Why Donald Trump's Putative FDA Pick Could Scare Pharma [Forbes]
|
|
|
|
|
|
Pharmaceutical
executives complain about the drug approval process, but usually don’t
want to go anywhere close to a safety-only path. In practice, what they
want is for the FDA to return their calls, for bureaucratic delays to be
reduced, and to find the fastest and least expensive way to prove
safety and efficacy.
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Controversial impact factor gets a heavyweight rival [Nature]
|
|
|
|
|
|
Although
the index ranks journals with a formula that largely mimics the
influential Journal Impact Factor (JIF), it covers twice as many
journals — 22,000 to the JIF’s 11,000 — and its formula includes tweaks
that produce some notably different results, including lower scores for
some high-JIF journals.
|
|
|
|
|
|